| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/12/2009 | US20090068188 C-C chemokine receptor 3 proteins |
| 03/12/2009 | US20090068151 Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| 03/12/2009 | US20090068142 Compositions and methods for treating coronavirus infection and sars |
| 03/12/2009 | US20090068115 Amine Functionalized Superparamagnetic Nanoparticles for the Synthesis of Bioconjugates and Uses Therefor |
| 03/12/2009 | US20090068104 Substantially Homogeneous Bio-Affecting Material Having a Pre-Determined Ratio of Bioaffecting Component to Cell Targeting Component, the Method for Making Such a Material and the Method of its use |
| 03/12/2009 | CA2727971A1 Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits |
| 03/12/2009 | CA2698721A1 Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
| 03/12/2009 | CA2698707A1 Release of antibiotic from injectable, biodegradable polyurethane scaffolds for enhanced bone fracture healing |
| 03/12/2009 | CA2698670A1 A novel controlled release-niacin formulation |
| 03/12/2009 | CA2698651A1 Eye drop containing dibenz [b,e] oxepin derivative |
| 03/12/2009 | CA2698498A1 Antiviral topical formulations in the form of a bio-adhesive gel |
| 03/12/2009 | CA2698396A1 Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof |
| 03/12/2009 | CA2698173A1 Interferon alpha 2b modified by polyethylene glycol, the preparation and use thereof |
| 03/12/2009 | CA2698108A1 Bi-functional polymer-attached inhibitors of influenza virus |
| 03/12/2009 | CA2696752A1 Complexes of rna and cationic peptides for stimulation of the innate immune system |
| 03/12/2009 | CA2695960A1 Vegfr-1/nrp-1 targeting peptides |
| 03/11/2009 | EP2033934A1 Hollow-fiber-like organic nanotube and process for production thereof |
| 03/11/2009 | EP2033662A1 Transglutaminase mediated conjugation of peptides |
| 03/11/2009 | EP2033661A1 Methods of screening affinity marker libraries |
| 03/11/2009 | EP2033660A1 Functionalized nanoparticles for the inhibition of selectin-mediated cell adhesion |
| 03/11/2009 | EP2033648A2 Sustained release drug delivery system containing codrugs |
| 03/11/2009 | EP2033633A2 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| 03/11/2009 | EP2032987A2 Pharmacological treatment of cognitive impairment |
| 03/11/2009 | EP2032652A2 Crosslinked, degradable polymers and uses thereof |
| 03/11/2009 | EP2032606A2 Antibodies and immunoconjugates and uses therefor |
| 03/11/2009 | EP2032172A2 Leptomycin derivatives |
| 03/11/2009 | EP2032171A2 A process for manufacturing a delivery system for active components as part of an edible composition |
| 03/11/2009 | EP2032129A2 Compositions of phenylephrine useful for treatment of respiratory illness |
| 03/11/2009 | EP2032125A2 Ropinirole-containing pharmaceutical compositions in the form of a gel, uses thereof |
| 03/11/2009 | EP2032115A2 Compositions based on hyperbranched condensation polymers and novel hyperbranched condensation polymers |
| 03/11/2009 | EP2000036A9 Volatile sulfide production inhibitor and method for inhibiting the production of volatile sulfide using the inhibitor |
| 03/11/2009 | EP1888027B1 Medicated product for local use based on natural materials |
| 03/11/2009 | EP1786400B1 Pharmaceutical compositions for controlled release delivery of biologically active compounds |
| 03/11/2009 | EP1680097B1 Preparations for topical application and methods of delivering an active agent to a substrate |
| 03/11/2009 | EP1641463B1 Compositions in the form of a spray comprising a pharmaceutical agent at least one volatile silicone and a non-volatile oily phase |
| 03/11/2009 | EP1601698B1 Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| 03/11/2009 | EP1524981B1 Sustained release formulations comprising lamotrigine |
| 03/11/2009 | EP1478229B1 Improved synthesis of polyanhyrides |
| 03/11/2009 | EP1460992B1 Stabilized reverse micelle compositions and uses thereof |
| 03/11/2009 | EP1453519A4 Aqueous ifosfamide composition |
| 03/11/2009 | EP1411899B1 Taste masking composition |
| 03/11/2009 | EP1337237B1 Pharmaceutical preparations comprising corticosteroids and antiinfective agents |
| 03/11/2009 | EP1318801B1 Topical analgesic compositions containing aliphatic polyamines and methods of using same |
| 03/11/2009 | EP1313451B1 Milled particles |
| 03/11/2009 | EP1299081B9 Use of oligosaccharides to stimulate beta-endorphin production |
| 03/11/2009 | EP1221985B1 Conveyance of anti-infective activity to wound dressings |
| 03/11/2009 | EP1137403B1 Sustained release tablet containing hydrocolloid and cellulose ether |
| 03/11/2009 | EP1071763B1 Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates |
| 03/11/2009 | EP0988374B1 Hydrophilic composition containing protease produced by vibrio proteolyticus |
| 03/11/2009 | EP0847242B2 Sugar-free dragee-like products |
| 03/11/2009 | CN101384623A Process for the production of preformed conjugates of albumin and a therapeutic agent |
| 03/11/2009 | CN101384282A Method for production of a transformed cell |
| 03/11/2009 | CN101384281A Granules, tablets and metuod of producing the same |
| 03/11/2009 | CN101384276A Method for preparing insulin preparation for oral using |
| 03/11/2009 | CN101384275A Dissolution aids for oral peptide delivery comprising a biguanide |
| 03/11/2009 | CN101384255A Bladder cancer treatment using e09 and propanediol |
| 03/11/2009 | CN101384253A Disinfectant ointment |
| 03/11/2009 | CN101381454A Preparation method of ion type temperature-responsive hyperbranched polyether and/or polyester ether |
| 03/11/2009 | CN101381413A Modified recombinant human endostatin and use thereof |
| 03/11/2009 | CN101381412A Polymer/recombinant human erythropoietin couple |
| 03/11/2009 | CN101381409A N-terminally chemically modified protein compositions and methods |
| 03/11/2009 | CN101380476A Albumin-binding derivatives of therapeutic peptides |
| 03/11/2009 | CN101380475A Preparation method of film coating pre-mixing agent and uses thereof |
| 03/11/2009 | CN101380474A A pH sensitive solid medicine composition for oral liquid and preparation method thereof |
| 03/11/2009 | CN101380473A Gold nano-bar based medicine carrier and preparation technique and use thereof |
| 03/11/2009 | CN101380376A Wean Qingkailing dispersible tablets |
| 03/11/2009 | CN101380375A External traditional Chinese medicine preparation for treating bone and soft tissue injury and preparation method thereof |
| 03/11/2009 | CN101380360A Total salvianolic acid drop pills and preparation method thereof |
| 03/11/2009 | CN101380358A Disinsection composition with synergistic action |
| 03/11/2009 | CN101380340A Wall-broken glossy ganoderma spore powder antioxidation method |
| 03/11/2009 | CN101380310A Composition of bFGF modified liposome and shRNA expression vector targeting human VEGF gene and preparation method thereof |
| 03/11/2009 | CN101380309A Metered dose inhalation aerosol and preparation method thereof |
| 03/11/2009 | CN101380308A Anticancer sustained-release preparation loaded with anti-cancer medicine and synergist thereof |
| 03/11/2009 | CN101380307A Anticancer sustained-release formulation loaded with anti-cancer medicine and synergist thereof |
| 03/11/2009 | CN101380304A Anticancer sustained-released formulation loaded with blood vessel inhibitor and synergist thereof |
| 03/11/2009 | CN101380299A Sustained-release injection containing methotrexate and synergist thereof |
| 03/11/2009 | CN101380298A Methotrexate sustained-release injection |
| 03/11/2009 | CN101380297A Compound platinum medicine sustained-release agent |
| 03/11/2009 | CN101380296A Anticancer sustained-release formulation loaded with platinum compound and synergist thereof |
| 03/11/2009 | CN101380295A Anti-cancer medicine sustained-release injection loaded with platinum compound and synergist thereof |
| 03/11/2009 | CN101380293A 10-acetyl-dithranol hydrogel and preparation method thereof |
| 03/11/2009 | CN101380291A Sustained-release injection and preparation method thereof |
| 03/11/2009 | CN101380290A Novel controlled release-niacin formulation |
| 03/11/2009 | CN100467538C Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| 03/11/2009 | CN100467494C Organic medicine and betacyclodextrin derivative and preparation process thereof |
| 03/11/2009 | CN100467490C Solid phase synthesis method of peptide-spacer-lipoid conjugate, synthesized conjugate and targeting liposome containing the conjugate |
| 03/11/2009 | CN100467476C Derivatives of branched-chain lipophilic molecules and uses thereof |
| 03/11/2009 | CN100467073C Implants with a phosphazene-containing coating |
| 03/11/2009 | CN100467066C Eye drip liquid which improves permeability by containing agar |
| 03/11/2009 | CN100467065C Non-gelatin capsule shell formulation comprising iota-carrageenan and kappa-carrageenan |
| 03/11/2009 | CN100467020C Matrix type patch containing bronchodilators |
| 03/11/2009 | CN100467016C Method and preparation for binding acetaldehyde in saliva, stomach and large intestine |
| 03/11/2009 | CN100466915C Menthyl half acid ester dirivatives, processes for preparing same, and uses thereof for their cooling/refreshing effect in consumable materials |
| 03/11/2009 | CA2716662A1 Polymer paclitaxel conjugates and methods for treating cancer |
| 03/10/2009 | US7501498 Moncolonal antibody for use in diagnosis and treatment of cell proliferative disorders; immunotherapy; tissue engineering |
| 03/10/2009 | US7501493 Dried blood factor composition comprising trehalose |
| 03/10/2009 | US7501485 Wound heraling agents; polypeptide |
| 03/10/2009 | US7501455 For parental injection of water insoluble drugs such as paclitaxel, propofol, amphotericin B, camptothecin, gemfibrozil and cyclosporin A; plasma protein such as serum albumin, an immunoglobulin, a glycoprotein, an interferon, or an interleukin, in controlled aggregation state |
| 03/10/2009 | US7501409 A tablet has an acid, with reduced solubility in the neutral and alkaline regions, is used for treating sexual disorders erectile dysfunction |
| 03/10/2009 | US7501403 Bile acid or bile salt fatty acid conjugates |